Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07115069 · ClinicalTrials.gov registry record

Comparison of Body Composition Changes With Weight Loss Interventions

A clinical trial of Obesity, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT07115069: Recruiting study of Obesity, sponsored by Vanderbilt University Medical Center.

NCT07115069 is a study of Obesity that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07115069, a study of Obesity, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways. The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels. The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.

Primary Outcome

loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 6 months as determined by DXA

Conditions Studied

Interventions

  • DRUG GLP-1 receptor agonist
  • PROCEDURE Gastric Bypass Surgery (laparoscopic)
  • PROCEDURE Gastric Bypass Surgery (robotic)

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-08-09
Est. Completion 2027-01

What NCT07115069 shows while recruiting

NCT07115069 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which GLP-1 receptor agonist is the first listed.

NCT07115069 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT07115069 about?

NCT07115069 is a clinical study titled "Comparison of Body Composition Changes With Weight Loss Interventions". This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or ...

What is the current status of trial NCT07115069?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-08-09. Estimated completion is 2027-01.

What conditions does trial NCT07115069 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT07115069?

The interventions under investigation include: GLP-1 receptor agonist (DRUG), Gastric Bypass Surgery (laparoscopic) (PROCEDURE), Gastric Bypass Surgery (robotic) (PROCEDURE).

Who is sponsoring clinical trial NCT07115069?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07115069 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07115069's enrollment target sits among peer trials

60 642nd of 1053 higher than 374 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07115069, the US trial registry maintained by the National Library of Medicine. NCT07115069 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.